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Abstract
Immune checkpoint inhibitors have improved the prognosis of advanced melanoma. 
Although anti–programmed death ligand‐1 (PD‐L1) is a well‐studied biomarker for re‐
sponse to anti–programmed death‐1 PD‐1 therapy in melanoma, its clinical relevance 
remains unclear. It has been established that the high expression of indoleamine 
2,3‐dioxygenase (IDO) is correlated to a response to anti–CTLA‐4 treatment in mela‐
noma. However, it is still unknown whether the IDO expression is associated with 
response to anti–PD‐1 therapy in advanced melanoma. In addition, acral and mucosal 
melanomas, which comprise a great proportion of all melanomas in Asians, are geneti‐
cally different subtypes from cutaneous melanomas; however, they have not been 
independently analyzed due to their low frequency in Western countries. To evaluate 
the association of IDO and PD‐L1 expression with response to anti–PD‐1 antibody in 
acral and mucosal melanoma patients, we analyzed 32 Japanese patients with acral 
and mucosal melanomas treated with anti–PD‐1 antibody from the perspective of 
IDO and PD‐L1 expression levels by immunohistochemistry (IHC). Multivariate Cox 
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1  | INTRODUC TION
Immune checkpoint inhibitors have revolutionized the treatment 
of advanced melanomas. Anti–cytotoxic T lymphocyte‐associated 
antigen‐4 (CTLA‐4) and anti–programmed death‐1 (PD‐1) therapy 
provided durable responses in approximately 10% and 33%‐40% 
of advanced melanoma patients, respectively,1‐3 indicating that im‐
mune checkpoint inhibitors are effective for only a certain subset 
of patients. In addition, immune checkpoint inhibitors frequently 
exhibit immune‐related cytotoxicities.1‐3 Therefore, predictive bio‐
markers for responses to immune checkpoint inhibitors are urgently 
needed to select suitable candidates. Although programmed death 
ligand‐1 (PD‐L1) is a well‐studied biomarker for response to anti–
PD‐1 therapy in melanoma, there are contradicting reports on its 
clinical relevance.4,5 Several reports show that other possible bio‐
markers could predict the response to treatment with anti–PD‐1 an‐
tibody in melanomas, such as tumor‐infiltrating CD8+ T cells, BRCA2 
mutation, HLA‐A allele, monocytes in blood, and blood neutrophil‐
to‐lymphocyte ratio combined with serum lactate dehydrogenase 
(LDH) level.6‐10 However, the relevance of these biomarkers in clini‐
cal practice and their routine application remain unclear.
Indoleamine 2,3‐dioxygenase (IDO) is a critical step in the ky‐
nurenine pathway that metabolizes tryptophan.11,12 IDO shows im‐
mune‐suppressive activities by negatively modulating effector T cell 
function and enhancing the regulatory T cell activities through the 
tryptophan metabolites.11,12 IDO is expressed in tumor cells, den‐
dritic cells, macrophages and endothelial cells in the tumor microen‐
vironment.12 IDO is expressed in both tumor cells and immune cells 
in melanomas.13 A positive correlation between the high expression 
of IDO and clinical response to anti–CTLA‐4 therapy in melanoma 
has been reported.14 However, the association of IDO expression 
with response to anti–PD‐1 therapy in melanoma remains unclear.
Acral and mucosal melanomas have not been analyzed inde‐
pendently from other types of melanomas in most clinical trials due 
to their low frequency in Western countries; however, they com‐
prise a great proportion of all melanomas diagnosed in Asians.2,3,15‐19 
Hayward et al20 show that acral and mucosal melanomas differ 
starkly from cutaneous melanomas in terms of mutational burden, 
structural variant, mutational signature and driver mutations. 
Therefore, focusing on acral and mucosal melanomas may provide 
insights specific to these subtypes.
In this study, we analyzed Japanese patients with acral 
and mucosal melanomas treated with anti–PD‐1 antibody. 
Immunohistochemistry (IHC) was performed to assess the associ‐
ation of the IDO and PD‐L1 expression with response to anti–PD‐1 
therapy.
2  | MATERIAL S AND METHODS
2.1 | Patients and samples
Eligible patients were those with unresectable acral or mucosal 
melanomas who initiated anti–PD‐1 therapy between 2015 and 
2017 at the Kyoto University Hospital and 8 participating hospitals. 
Other eligibility criteria included an Eastern Cooperative Oncology 
Group (ECOG) performance status (PS) score of 0 or 1, and the 
availability of formalin‐fixed, paraffin‐embedded tumor specimens 
within 2 months before the first treatment of anti–PD‐1 antibody 
nivolumab. Patients received anti–PD‐1 therapy at either 3 mg/kg 
dosing every 2 weeks or at 2 mg/kg dosing every 3 weeks. Tumors 
were assessed according to the Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.1.21 Responders were defined as patients 
who had a complete response (CR) or partial response (PR) as their 
best overall response. The objective response rate (ORR) was de‐
fined as the proportion of patients who achieved a CR or PR as their 
best overall response. This study was approved by the ethics com‐
mittee of the Kyoto University Graduate School of Medicine and 
participating institutions. Written informed consent was obtained 
from all patients.
2.2 | Immunohistochemical analysis
Immunohistochemistry was performed using formalin‐fixed, paraf‐
fin‐embedded tumor specimens with BOND RX Fully Automated 
regression models showed that the low expression of IDO in tumors was associ‐
ated with poor progression‐free survival (HR = 0.33, 95% CI = 0.13‐0.81, P = 0.016), 
whereas PD‐L1 expression on tumors was not associated with progression‐free sur‐
vival. Significantly lower expression of IDO in tumors was found in non–responders 
compared to responders. Assessment of the IDO expression could be useful for the 
identification of suitable candidates for anti–PD‐1 therapy among acral and mucosal 
melanomas patients. Further validation study is needed to estimate the clinical utility 
of our findings.
K E Y W O R D S
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Research Stainer (Leica). Antigen retrieval was performed using 
BOND Epitope Retrieval Solution 2 (Leica). In the IDO analysis, slides 
were incubated with the primary antibody against IDO (Clone 10.1; 
Merck Millipore) at a 1:250 dilution for 15 minutes. Mouse IgG1, 
kappa (Clone MOPC‐21; BioLegend) was used as an isotype control. 
Signals were generated by BOND Polymer Refine Red Detection 
(Leica). In PD‐L1 analysis, slides were incubated with the primary 
antibody against PD‐L1 (Clone SP142; Spring Bioscience) at a 1:100 
dilution for 60 minutes. Rabbit polyclonal IgG (ab27478; Abcam) was 
used as an isotype control. Next, the ImmPRESS‐AP Anti–Rabbit IgG 
Polymer Detection Kit (Vector Laboratories) was used as a second 
antibody. Signals were generated by ImmPACT Vector Red Alkaline 
Phosphatase Substrate (Vector Laboratories). The sections were 
counterstained with hematoxylin.
2.3 | Scoring of the indoleamine 2,3‐
dioxygenase and anti–programmed death ligand‐1 
expression in melanoma
The images were captured with an automated slide scanner, 
Nanozoomer (Hamamatsu Photonics). In the previous reports, 
IDO− was defined as IDO negative, IDO+ as IDO staining in <25% 
of tumor or antigen‐presenting cells, IDO++ as IDO staining in 
25%‐50% and IDO+++ as IDO staining in >50%.13,22 Because there 
was no case matching IDO++ in our study, we modified the criteria 
as follows: IDO− as IDO negative, IDO+ as IDO staining in <25% of 
tumor or peritumoral mononuclear inflammatory cells and IDO++ 
as ≥25% (Figure 1A‐C). Melanoma patients were dichotomized 
into the high IDO expression group as IDO++ and the low IDO ex‐
pression group as IDO− and IDO+. Endothelial IDO expression in 
the peritumoral stroma was dichotomized as “present” or “absent” 
following the criteria described previously.23 PD‐L1 positivity was 
defined as a membranous PD‐L1 staining in at least 5% of tumors 
(Figure 1D,E).2,24
2.4 | Statistical analysis
Survival curves were generated using the Kaplan‐Meier method. 
Progression‐free survival (PFS) was defined as the time from the first 
treatment of anti–PD‐1 antibody to documented tumor progression or 
death. Patients were censored if they showed no sign of the disease 
progression on the last evaluation or if the patients were lost to follow 
F I G U R E  1   Indoleamine 2,3‐dioxygenase (IDO) and programmed death ligand‐1 (PD‐L1) expression by immunohistochemistry (IHC). 
Representative IHC images of IDO++, IDO+ and IDO− in tumors and in peritumoral mononuclear inflammatory cells are shown (A‐C). 
Representative IHC staining of PD‐L1(≥5%) and PD‐L1(<5%) on tumors are shown (D, E)
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up. A two‐sided Fisher's exact test was used for exploring the asso‐
ciation between clinical variables and the IDO expression and the as‐
sociation between the IDO expression and the best overall response. 
Cox‐proportional hazard regression models were used to examine the 
relationships among IDO expression, PD‐L1 expression and PFS with 
adjustment for possible confounders (the level of LDH and ECOG PS). 
Spearman's rank correlation was used to examine the relation between 
PD‐L1 and IDO expression in tumors. P < 0.05 was considered statisti‐
cally significant. Statistical analysis was performed using R statistical 
software (R Foundation for Statistical Computing).
Variables Total (n = 32)
IDO expression in tumor






≤65 y 13 8 2 3 0.46
>65 y 19 7 4 8
Sex
Male 17 8 3 6 1.00
Female 15 7 3 5
ECOG performance status
0 24 11 4 9 0.87
1 8 4 2 2
Metastatic stage
M0 5 2 0 3 0.69
M1a 9 5 2 2
M1b 3 2 1 0
M1c 15 6 3 6
Lactate dehydrogenase
≤ULN 20 9 3 8 0.71
>ULN 12 6 3 3
≤2xULN 28 13 5 10 1.00
>2xULN 4 2 1 1
History of brain metastasis
Yes 2 2 0 0 0.73
No 29 12 6 11
Unknown 1 1 0 0
Subtype
Acral 15 7 2 6 0.81
Mucosal 17 8 4 5
BRAF mutational status
Mutation 4 3 0 1 0.64
No mutation 28 12 6 10
Prior systemic therapy
BRAF inhibitor 1 1 0 0 0.20
Chemotherapy 6 2 3 1
None 25 12 3 10
PD‐L1 expression
<5% 22 14 4 4 0.004
≥5% 10 1 2 7
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IDO, indoleamine 2,3‐dioxygenase; 
PD‐L1, programmed death ligand‐1; ULN, upper limit of the normal range.
Bold values denote statistical significance at the P < 0.05 level.
TA B L E  1   Patient characteristics and 
association with IDO expression in tumors
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3  | RESULTS
3.1 | Patient characteristics
We enrolled 15 patients with acral melanoma and 17 patients with 
mucosal melanoma (Table 1). The median follow up was 10.3 months, 
with the database lock on 28 December 2017. This study included 
17 men (53%), and the BRAFV600E mutation was found in 4 patients 
(12.5%). A total of 15 patients (47%) had stage M1c disease, 12 pa‐
tients (37.5%) had an elevated LDH level and 2 patients (6.2%) had 
brain metastases. A total of 7 patients (21.9%) had prior systemic 
treatments; 1 patient (3.1%) received BRAF inhibitor and 6 patients 
(18.8%) received dacarbazine‐based chemotherapy. The median PFS 
was 3.73 months (3.96 months in acral melanoma and 3.73 months 
in mucosal melanoma). The ORR was 33% (95% confidence interval 
[CI]: 12%‐61%) in acral melanomas and 26% (7.8%‐55%) in mucosal 
melanomas.
3.2 | Indoleamine 2,3‐dioxygenase and anti–
programmed death ligang‐1 were expressed 
by melanoma
Formalin‐fixed, paraffin‐embedded tumor specimens within 
2 months before the first treatment of anti–PD‐1 antibody were 
stained for IDO and PD‐L1. IDO was expressed in tumors and in 
mainly inflammatory mononuclear cells of peritumoral tissues as 
determined by their morphologies. A total of 10 patients (31.2%) 
were classified as IDO−, 11 patients (34.4%) as IDO+ and 11 pa‐
tients (34.4%) as IDO++ in tumors (Table 1) (Figure 1A‐C). A total 
of 23 samples contained peritumoral tissues sufficient for evalu‐
ation of IDO expression in peritumoral tissue; 11 patients (47.8%) 
were classified as IDO−, 4 patients (17.4%) as IDO+ and 8 patients 
(34.8%) as IDO++ in peritumoral mononuclear inflammatory cells 
(Figure 1A‐C). A total of 20 patients (87.0%) were classified as IDO 
positive and 3 patients (13.0%) as IDO negative in endothelial cells. 
F I G U R E  2   Association of indoleamine 2,3‐dioxygenase (IDO) expression and programmed death ligand‐1 (PD‐L1) expression with 
response to anti–PD‐1 therapy. The Kaplan‐Meier progression‐free survival (PFS) curve stratified by the IDO expression in tumor is shown 
(n = 32) (A). The IDO expression in tumors in responders and non–responders is shown (B). The Kaplan‐Meier PFS curves stratified by the 
IDO expression in peritumoral mononuclear inflammatory cells (n = 23) (C) and PD‐L1 expression on tumors (n = 32) (D) are shown. The log‐
rank test was performed for the univariate analysis
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A total of 12 cases (37.5%) were PD‐L1‐positive (Figure 1D,E). PD‐L1 
expression was positively correlated with IDO expression in tumors 
(rho = 0.53; P < 0.01, Spearman's rank correlation) (Table 1).
3.3 | Low expression of indoleamine 2,3‐
dioxygenase and in tumors was associated with poor 
progression‐free survival and poor response to anti–
programmed death‐1 therapy
We examined whether the IDO and PD‐L1 expressions were asso‐
ciated with response to anti–PD‐1 antibody nivolumab in 32 acral 
and mucosal melanoma patients. We found that the low IDO expres‐
sion in tumors was associated with poor PFS (P = 0.007, log rank 
test) (Figure 2A). The low expression of IDO in tumors showed a 
tendency toward poor PFS in acral melanomas (n = 15, P = 0.027) 
and mucosal melanomas (n = 17, P = 0.113). The median PFS was 
13.3 months in the high IDO expression group and 2.9 months in the 
low IDO expression group. The IDO expression in tumors was inde‐
pendent of age, sex, ECOG PS, metastatic stage, LDH, a history of 
brain metastasis, subtype (acral or mucosal), BRAF mutational status 
and prior systemic therapy (Table 1). Univariate Cox‐proportional 
hazard regression analysis revealed that an elevated LDH, ECOG PS 
and low expression of IDO were associated with poor PFS (Table 2). 
Multivariate Cox‐proportional hazard regression analysis revealed 
that the low expression of IDO in tumors was significantly associated 
with poor PFS, after adjustments with the level of LDH and ECOG PS 
(hazard ratio [HR] = 0.33, P = 0.016, 95% CI = 0.13‐0.81) (Table 3). 
Lower expression of IDO in tumors was observed in non–responders 
to anti–PD‐1 therapy compared to responders (P = 0.031, by Fisher's 
exact test) (Figure 2B). The ORR was 54% (95% CI: 23%‐83%) in the 
high IDO expression group and 15% (95% CI: 3.4%‐39%) in the low 
IDO expression group. Although not statistically significant, cases 
with endothelial IDO expression in the peritumoral stroma showed 
a tendency toward longer PFS (Figure S1) (Table 4). We found that 
IDO expression in peritumoral mononuclear inflammatory cells was 
not associated with PFS (Figure 2C). Moreover, PD‐L1 expression 
on tumor cells was not associated with PFS (Figure 2D) (Table 5). 
These results suggest that the IDO expression in tumors was cor‐
related with response to anti–PD‐1 therapy in acral and mucosal 
melanomas.
  HR 95% P‐value
Age ≤65 y vs >65 y 0.77 0.34‐1.73 0.53
Sex Male vs female 0.88 0.41‐1.9 0.76
LDH ≤ULN vs >ULN 3.27 1.46‐7.63 0.004
≤2ULN vs >2ULN 5.03 1.59‐15.94 0.006
ECOG performance status 0 vs 1 2.37 1.01‐5.6 0.04
M stage M0 vs M1a,b,c 2.64 0.78‐8.9 0.11
History of brain metastasis Absent vs present 4.57 0.47‐44 0.18
Subtype Acral vs mucosal 1.16 0.5‐2.5 0.68
BRAFV600E mutation Absent vs present 0.58 0.17‐1.96 0.38
Chemotherapy before 
nivolumab
Absent vs present 0.85 0.41‐1.72 0.65
IDO expression in tumor 0, + vs ++ 0.38 0.16‐0.89 0.026
IDO expression in 
peritumoral inflammatory 
mononuclear cells
0, + vs ++ 0.84 0.57‐1.23 0.37
PDL1 expression on tumor <5% vs ≥5% 0.60 0.27‐1.33 0.21
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IDO, indoleamine 2,3‐dioxygenase; 
LDH, lactate dehydrogenase; PD‐L1, programmed death ligand‐1.
Bold values denote statistical significance at the P < 0.05 level.
TA B L E  2   Univariate Cox regression 
analysis of prognostic factors for 
progression‐free survival in acral and 
mucosal melanoma patients
  HR 95% CI P‐value
LDH ≤ULN vs >ULN 3.97 1.65‐9.54 0.002
ECOG performance 
status
0 vs 1 2.00 0.82‐4.86 0.12
IDO expression in 
tumor
0, + vs ++ 0.33 0.13‐0.81 0.016
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IDO, indoleamine 2,3‐dioxygenase; 
LDH, lactate dehydrogenase
Bold values denote statistical significance at the P < 0.05 level.
TA B L E  3   Multivariate Cox regression 
analysis of prognostic factors including 
IDO expression in tumor for progression‐
free survival in acral and mucosal 
melanoma patients
3440  |     IGA et Al.
4  | DISCUSSION
In this study, we showed that the low expression of IDO in tumors 
was associated with poor PFS in Japanese acral and mucosal mela‐
noma patients treated with anti–PD‐1 therapy, whereas the PD‐L1 
expression on tumors was not associated with PFS. This finding sug‐
gests that assessment of the IDO expression could be useful for the 
identification of candidates for anti–PD‐1 therapy among acral and 
mucosal melanoma patients, which comprise a great proportion of 
all melanomas in Asia.15‐19
Indoleamine 2,3‐dioxygenase facilitates immune escape by de‐
pleting tryptophan in tumor microenvironment.25 There are con‐
flicting reports regarding the relevance of IDO as a biomarker. A 
recent study demonstrated that the IDO expression in cutaneous 
melanoma was correlated with shorter PFS.13 Another study found 
that endothelial expression of IDO was correlated with shorter 
overall survival.23 On the other hand, Hamid et al14 reported 
that IDO expression was associated with clinical response in ad‐
vanced melanoma patients treated with anti–CTLA‐4 antibody. 
Our finding is in accordance with the latter study; we found that 
the IDO expression in tumors was correlated with longer PFS in 
acral and mucosal melanoma patients treated with anti–PD‐1 an‐
tibody. Moreover, cases with endothelial IDO expression showed 
a tendency toward longer PFS. This discrepancy in the role of IDO 
can be explained by the context of the studies. Studies report‐
ing on the negative impact of IDO expression analyzed all mela‐
noma patients treated surgically while we and Hamid et al studied 
melanoma patients undergoing specific cancer immunotherapy. 
Patients with IDO expression are likely to recur due to the immu‐
nosuppressive environment if surgically treated. If the patients are 
to be treated with cancer immunotherapy, IDO expression indi‐
cates that there is an immunosuppressive environment that can be 
reverted by immunotherapy. The IDO expression could be a can‐
didate for biomarkers for response to anti–PD‐1 therapy among 
acral and mucosal melanoma patients.
Interestingly, our data showed that the frequency of the IDO ex‐
pression in tumors was lower in acral and mucosal melanomas than 
the reported frequency in cutaneous melanomas.13 The genetic dif‐
ferences between acral and mucosal melanomas and cutaneous mel‐
anomas may contribute to the IDO expression levels in tumors and in 
the peritumoral stroma. Although anti–PD‐1 inhibitor/IDO‐1 inhibitor 
combination therapy in phase I/II trials had encouraging antitumor 
activity in metastatic melanomas,26 the results of the phase 3 study 
did not detect the efficacy of them.27 Because our results showed the 
varying IDO expression profiles between major melanoma subtypes, 
anti–PD‐1 inhibitor/IDO‐1 inhibitor combination therapy targeted for 
specific strata of melanoma patients may merit consideration.
Programmed death ligand‐1 expression contributes to the impair‐
ment of effector functions of CD8+ tumor‐infiltrating lymphocytes 
when it binds to PD‐1.28 Although PD‐L1 is a well‐studied biomarker 
for checkpoint inhibitors, some reports reveal that the PD‐L1 status 
alone is not useful for the selection of patients for anti–PD‐1 ther‐
apy.2,3 We could not find an association between the PD‐L1 expression 
on tumors and the prognosis in acral and mucosal melanoma patients 
treated with anti–PD‐1 antibody. Therefore, the routine assessment 
of the IDO expression can be considered, particularly in acral and mu‐
cosal melanoma patients. There are several limitations in our study. 
First, a standardized method for the assessment of IDO expression is 
lacking, and this may adversely impact the generalizability of our study. 
Second, our study is limited by a small sample size (n = 32). Therefore, 
we propose that the relevance of biomarkers of the IDO expression in 
each subtype of melanoma should be evaluated in a large‐scale study.
In summary, this study demonstrated that the low expression 
of IDO in acral and mucosal melanomas was associated with poor 
PFS in Japanese acral and mucosal melanoma patients treated with 
anti–PD‐1 antibody. IDO could be a candidate for biomarkers for the 
response to anti–PD‐1 therapy in acral and mucosal melanoma pa‐
tients. Further study is needed to assess the clinical utility of our 
findings.
TA B L E  4   Multivariate Cox regression analysis of prognostic 
factors including endothelial IDO expression in the peritumoral 
stroma for progression‐free survival in acral and mucosal melanoma 
patients
  HR 95% CI P‐value
LDH ≤ULN vs >ULN 3.16 1.16‐8.58 0.02
ECOG perfor‐
mance status






Abbreviations: ECOG, Eastern Cooperative Oncology Group; IDO, 
indoleamine 2,3‐dioxygenase; LDH, lactate dehydrogenase.
Bold values denote statistical significance at the P < 0.05 level.
  HR 95% CI P‐value
LDH ≤ULN vs >ULN 3.13 1.24‐7.87 0.015
ECOG performance 
status
0 vs 1 2.34 0.97‐5.60 0.057
PDL1 expression on 
tumor
<5% vs ≥5% 0.90 0.37‐2.21 0.83
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PD‐L1, 
programmed death ligand‐1.
Bold values denote statistical significance at the P < 0.05 level.
TA B L E  5   Multivariate Cox regression 
analysis of prognostic factors including 
PD‐L1 expression on tumor for 
progression‐free survival in acral and 
mucosal melanoma patients
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